Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti-β2-glycoprotein I antibodies: a systematic evaluation according to the guidelines

Abstract

Background

Phadia/EliA fluorescence enzyme immunoassays are widely used automated assays for anticardiolipin (aCL) and anti-β2-glycoprotein I (aβ2GPI) antibodies. To date, cut-off values for these assays have not been evaluated systematically and the evidence behind manufacturer’s recommended cut-off values is not clear.

Objective

To determine Phadia/EliA cut-off values for antiphospholipid antibodies (aPL) according to the procedures suggested by guidelines.

Methods

A total of 266 blood donors (135 females and 131 males) were included. The pre-handling and analysis of the samples were performed according to the International Society on Thrombosis and Hemostasis (ISTH) guideline for solid phase aPL assays. Cut-off values and corresponding 90% confidence intervals (CI) for each antibody were established and outliers were handled according to the Clinical and Laboratory Standards Institute (CLSI) guideline for reference intervals. Samples from 377 consecutive patients, referred to our thrombophilia center with evidence of thrombosis or pregnancy morbidity were included for aPL testing.

Results

The in-house 99th (97.5th) percentile cut-off values were 11 (8.7), 12 (6.9) 8.5 (5.0) AU/mL for aβ2GPI IgG, IgM and IgA, and 21 (13) GPL-U/mL and 41 (25) MPL-U/mL for aCL IgG and IgM, respectively. The prevalence of positive results (%) defined by these cut-off values in patients with evidence of thrombosis or pregnancy morbidity was 9.5 (12.2), 1.6 (2.9), and 7.0 (9.9), and 0.8 (3.8) for aβ2GPI IgG, IgM, and aCL IgG and IgM respectively. The use of in-house 99th percentile cut-off values compared to the manufacturer suggested cut-off values resulted in 1 and 39 fewer samples for aβ2GPI and aCL to be classified as positive for aPL, respectively.

Conclusions

We present Phadia/EliA cut-off values with 90% CI for aPL determined systematically according to the ISTH and CLSI guidelines. These values are different from values previously determined, suggesting variation of aPLs in different populations. Our findings indicate the need for each laboratory to determine/validate assay specific cut-off values for aPL.

Keywords

Fluorescence enzyme immunoassay anticardiolipin anti-β2-glycoprotein I antibodies cut-off value

Get full access to this article

View all access options for this article.

References

Miyakis

Lockshin

Atsumi

Branch

Brey

Cervera

et al.

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Persijn

Decavele

Schouwers

Devreese

. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2011; 128: 565–569.

Villalta

Alessio

Tampoia

Da Re

Stella

Da Re

et al.

Accuracy of the first fully automated method for anti-cardiolipin and anti-beta2 glycoprotein I antibody detection for the diagnosis of antiphospholipid syndrome. Ann N Y Acad Sci 2009; 1173: 21–27.

Meneghel

Ruffatti

Gavasso

Bai

Zhang

. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-beta2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clin Chem Lab Med 2015; 53: 1083–1089.

Devreese

Poncet

Lindhoff-Last

Musial

de Moerloose

Fontana

. A multicenter study to assess the reproducibility of antiphospholipid antibody results produced by an automated system. J Thromb Haemost 2017; 15: 91–95.

UK NEQAS (2017) UK NEQAS for anti phospholipid antibodies. Available at: http://ulbld.lf1.cuni.cz/file/2841/neqas-apla.pdf (accessed November 2017).

Phadia GmbH (2011) EliA β2-Glycoprotein I IgM (package insert). Freiburg: Phadia GmbH. Available at: http://www.inter-2t.phadia.com/PageFiles/29279/EliA%20Beta%202-Glycoprotein1%20IgM.pdf (accessed November 2017).

Phadia GmbH (2011) EliA Cadiolipin IgM (package insert). Freiburg: Phadia GmbH. Available at: http://www.unicap.us/PageFiles/29279/EliA%20Cardiolipin%20IgM%20Well.pdf (accessed November 2017).

Phadia GmbH (2011) EliA Cardiolipin IgG (package insert). Freiburg: Phadia GmbH. Available at:. http://www.inter-2t.phadia.com/PageFiles/29279/EliA%20Cardiolipin%20IgG%20Well.pdf (accessed November 2017).

10.

Clinical and Laboratory Standards Institute (2015). Defining, establishing, and verifying reference intervals in the clinical laboratory, 3rd edition. CLSI document EP28-A3c. Wayne PA: Clinical and Laboratory Standards Institute.

11.

Devreese

Pierangeli

de Laat

Tripodi

Atsumi

Ortel

et al.

Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12: 792–795.

12.

Kalamkar SS, Singh PK and Banerjee A. Block outlier methods for malicious user detection in cooperative spectrum sensing. Vehicular Technology Conference (VTC Spring), 2014 IEEE 79th, Seoul, South Korea, 18–21 May 2014. Piscataway, NJ: Institute of Electrical and Electronics Engineers.

13.

Pengo

Banzato

Bison

Denas

Zoppellaro

Bracco

et al.

Laboratory testing for antiphospholipid syndrome. Int J Lab Hematol 2016; 38(Suppl 1): 27–31.

14.

Pierangeli

Favaloro

Lakos

Meroni

Tincani

Wong

et al.

Standards and reference materials for the anticardiolipin and anti-beta2glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta 2012; 413: 358–360.

15.

Willis

Grossi

Orietta Borghi

Martos-Sevilla

Zegers

Sheldon

et al.

International standards for IgG and IgM anti-beta2glycoprotein antibody measurement. Lupus 2014; 23: 1317–1319.

16.

Bertolaccini

Amengual

Andreoli

Atsumi

Chighizola

Forastiero

et al.

14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014; 13: 917–930.

17.

Willis

Pierangeli

Jaskowski

Malmberg

Guerra

Salmon

et al.

Performance characteristics of commercial immunoassays for the detection of IgG and IgM antibodies to beta2 glycoprotein I and an initial assessment of newly developed reference materials for assay calibration. Am J Clin Pathol 2016; 145: 796–805.

18.

Devreese

. Antiphospholipid antibody testing and standardization. Int J Lab Hematol 2014; 36: 352–363.

19.

Favaloro

Wong

. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011; 49: 447–461.

20.

Favaloro

Wong

. Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines. Pathology 2014; 46: 481–495.

21.

Lakos

Favaloro

Harris

Meroni

Tincani

Wong

et al.

International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012; 64: 1–10.

22.

Moore

. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014; 40: 163–171.

23.

Tincani

Filippini

Scarsi

Galli

Meroni

. European attempts for the standardisation of the antiphospholipid antibodies. Lupus 2009; 18: 913–919.

24.

Wong

Favaloro

Adelstein

Baumgart

Bird

Brighton

et al.

Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. Pathology 2008; 40: 58–63.

25.

Ruffatti

Olivieri

Tonello

Bortolati

Bison

Salvan

et al.

Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008; 6: 1693–1696.

26.

Pengo

Tripodi

Reber

Rand

Ortel

Galli

et al.

Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–1740.

27.

Montaruli

De Luna

Mengozzi

Molinari

Napolitano

Napoli

et al.

Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: normal reference ranges in northwestern Italy. Lupus 2012; 21: 799–801.

28.

Damoiseaux

Peeters

Hupperts

Boreas

ten Cate

Tervaert

. Prevalence of anticardiolipin antibodies in patient cohorts with distinct clinical manifestations of the antiphospholipid syndrome. Ann N Y Acad Sci 2009; 1173: 146–151.

29.

Murthy

Willis

Romay-Penabad

Ruiz-Limón

Martínez-Martínez

Jatwani

et al.

Value of isolated IgA anti-beta2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 2013; 65: 3186–3193.

30.

Mattia

Ruffatti

Tonello

Meneghel

Robecchi

Pittoni

et al.

IgA anticardiolipin and IgA anti-beta2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome. Clin Chem Lab Med 2014; 52: 1329–1333.